Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (18)

2023

  1. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  2. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

  3. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61

  4. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117

2022

  1. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

    Breast, Vol. 63, pp. 123-139

  2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

    The Lancet Oncology, Vol. 22, Núm. 1, pp. e18-e28

  2. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

  3. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  4. The Impact of the COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future Perspectives

    Oncologist, Vol. 26, Núm. 1, pp. e66-e77

2020

  1. Implementation of the BRESO Theoretical and practical knowledge curriculum for European Breast Surgeons: The time has come

    European Journal of Surgical Oncology

2019

  1. Breast-implant associated anaplastic large-cell lymphoma. Consensus document (I). Epidemiology, pathogenesis, symptoms and diagnosis

    Revista de Senologia y Patologia Mamaria, Vol. 32, Núm. 2, pp. 61-66

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

    Annals of Oncology, Vol. 29, Núm. 2, pp. 405-417

  3. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy

    Breast Cancer Research and Treatment, Vol. 172, Núm. 3, pp. 523-537

  4. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  5. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2014

  1. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

    Journal of the National Cancer Institute, Vol. 106, Núm. 11